Abbott Laboratories Corporation

Keeve D Jaffe

Dominique P Bridon

John C Russell

George J Dawson

Tracey L Colpitts

Tami J Pilot-Matias

Isa K Mushahwar

Catherine A Brennan

Grant A Krafft

Elaine Marie Brate

Steven C March

Wlodzimierz Mandecki

David J Daghfal

Mark F Knigge

Vincent T Yue

Pamella A Schroeder-Poliak

Isaac S-y Sze, Deceased

This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate. The ligand binds with an antibody, an analyte or a binding molecule to an analyte and as a result of this binding, the enzymatic activity of the hybrid enzyme-ligand conjugate is modified or modulated.

Genetically engineered enzymes and their conjugates for diagnostic assays

Hepatitis GB Virus (HGBV) synthetic peptides useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV peptides.

Hepatitis GB Virus synthetic peptides and uses thereof

HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.

Peptides for HIV-1 detection

Growing community of inventors

Trevor, WI, United States of America

Keeve D Jaffe